Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978801 | 1.00 | DNM1 (0.48) | DNM1USP2HTTTSHRMEN1 | |
| SCHEMBL5596274 | 1.00 | DNM1 (0.48) | DNM1USP2HTTTSHRMEN1 | |
| SCHEMBL1095723 | 1.00 | DNM1 (0.48) | DNM1USP2HTTTSHRMEN1 | |
| SCHEMBL4100169 | 1.00 | DNM1 (0.48) | DNM1USP2HTTTSHRMEN1 | |
| SCHEMBL6021620 | 1.00 | DNM1 (0.48) | DNM1USP2HTTTSHRMEN1 | |
| SCHEMBL23038765 | 1.00 | DNM1 (0.48) | DNM1USP2HTTTSHRMEN1 | |
| SCHEMBL4635532 | 1.00 | DNM1 (0.48) | DNM1USP2HTTTSHRMEN1 | |
| SCHEMBL4582497 | 1.00 | DNM1 (0.48) | DNM1USP2HTTTSHRMEN1 | |
| SCHEMBL1095934 | 0.98 | DNM1 (0.45) | DNM1USP2HTTTSHRMEN1 | |
| Ethylene Glycol SCHEMBL15090416 | 0.94 | MEN1 (0.47) | DNM1USP2HTTTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | claimed |
| US-20150051174-A1 | Phosphonate Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | claimed |
| US-8889658-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-18 | — | — | US | claimed |
| US-8710030-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-29 | — | — | US | claimed |
| US-20140045794-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | claimed |
| US-7687480-B2 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-30 | — | — | US | claimed |
| US-20080071084-A1 | Using an alcohol in presence of copper catalyst and ligand | ARCHIMICA GMBH (DE) | 2008-03-20 | — | — | US | claimed |
| EP-1233770-B1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA AT SAN DIEGO (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1873136-A1 | Method for manufacturing alkyl and aryl ethers | Archimica GmbH (DE) | 2008-01-02 | — | — | EP | claimed |
| US-7034014-B2 | New derivatives of cidofovir, adefovir, cyclic cidofovir or tenofovir made by forming phosphonate ester with an alcohol such as alkylglycerol, alkylpropanediol, 1-S-alkylthioglycerol, alkoxyalkanol or alkylethanediol; e.g. 1-O-octadecylpropanediol-3-cidofovir; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-25 | — | — | US | claimed |
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | VIROVET NV (BE) | 2025-06-26 | — | — | US | disclosed |
| EP-4518869-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | ViroVet NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2023214017-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | VIROVET NV (BE) | 2023-11-09 | — | — | WO | disclosed |
| CN-110655546-B | Sofosbuvir derivative, and preparation method and application thereof | 安徽贝克制药股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-6716825-B2 | OSTEOPOROSIS AND OTHER DISORDERS OF BONE METABOLISUM, CANCER, VIRAL INFECTIONS, AND THE LIKE. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-06 | — | — | US | disclosed |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1233770-A4 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA AT SAN DIEGO (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1233770-A2 | PHOSPHONATE COMPOUNDS | The Regents of The University of California at San Diego (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001039724-A2 | PHOSPHONATE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051174-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | DNM1 777/4885USP2 4514/4885HTT 3374/4885 |
| US-20140045794-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | DNM1 777/4885USP2 4514/4885HTT 3374/4885 |
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | ATIC, PIGS, TYMP | DNM1 2862/4885USP2 3407/4885HTT 4602/4885 |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | BPGM, PPA1, INPP5D | DNM1 329/4885USP2 4456/4885HTT 4838/4885 |
| US-20080071084-A1 | Using an alcohol in presence of copper catalyst and ligand | NR1H3, NR1H2, ADH1A | DNM1 2704/4885USP2 2205/4885HTT 4482/4885 |
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | DNM1 3698/4885USP2 1915/4885HTT 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.